

RESEARCH

Open Access



# Network alterations underlying anxiety symptoms in early multiple sclerosis

Erik Ellwardt<sup>1†</sup>, Muthuraman Muthuraman<sup>2\*†</sup> , Gabriel Gonzalez-Escamilla<sup>3</sup>, Venkata Chaitanya Chirumamilla<sup>3</sup>, Felix Luessi<sup>1</sup>, Stefan Bittner<sup>1</sup>, Frauke Zipp<sup>1</sup>, Sergiu Groppa<sup>3</sup> and Vinzenz Fleischer<sup>1</sup>

## Abstract

**Background:** Anxiety, often seen as comorbidity in multiple sclerosis (MS), is a frequent neuropsychiatric symptom and essentially affects the overall disease burden. Here, we aimed to decipher anxiety-related networks functionally connected to atrophied areas in patients suffering from MS.

**Methods:** Using 3-T MRI, anxiety-related atrophy maps were generated by correlating longitudinal cortical thinning with the severity of anxiety symptoms in MS patients. To determine brain regions functionally connected to these maps, we applied a technique termed “atrophy network mapping”. Thereby, the anxiety-related atrophy maps were projected onto a large normative connectome ( $n = 1000$ ) performing seed-based functional connectivity. Finally, an instructed threat paradigm was conducted with regard to neural excitability and effective connectivity, using transcranial magnetic stimulation combined with high-density electroencephalography.

**Results:** Thinning of the left dorsal prefrontal cortex was the only region that was associated with higher anxiety levels. Atrophy network mapping identified functional involvement of bilateral prefrontal cortex as well as amygdala and hippocampus. Structural equation modeling confirmed that the volumes of these brain regions were significant determinants that influence anxiety symptoms in MS. We additionally identified reduced information flow between the prefrontal cortex and the amygdala at rest, and pathologically increased excitability in the prefrontal cortex in MS patients as compared to controls.

**Conclusion:** Anxiety-related prefrontal cortical atrophy in MS leads to a specific network alteration involving structures that resemble known neurobiological anxiety circuits. These findings elucidate the emergence of anxiety as part of the disease pathology and might ultimately enable targeted treatment approaches modulating brain networks in MS.

**Keywords:** Multiple sclerosis, Anxiety, Atrophy, Functional connectivity, Excitability

## Introduction

Multiple sclerosis is a demyelinating autoimmune disease of the CNS leading to disability in young adults. Sensory and motor deficits are characteristic symptoms, but also cognitive and neuropsychiatric symptoms can occur, even in early disease stages [1–4]. With regard to affective symptoms, anxiety is considered a major debilitating symptom in multiple sclerosis, impairing quality of life [5–7]. Moreover, a large number of patients develop anxiety symptoms years before clinical disease manifestation or motor symptoms [8]. Interestingly, anxiety, although

<sup>†</sup>Erik Ellwardt and Muthuraman Muthuraman are first authors and contributed equally to this work

\*Correspondence: mmuthura@uni-mainz.de

<sup>2</sup>Biomedical Statistics and Multimodal Signal Processing Unit, Department of Neurology, Focus Program Translational Neuroscience (FTN) Neuroimaging Center, Rhine Main Neuroscience Network (rmn2), University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

often still seen as co-morbidity, is however associated with the long-term development of cognitive impairment and memory deficits [6, 9]. Cognitive deficits, in turn, are clearly related to neurodegeneration [10]. Therefore, early neurodegenerative processes in multiple sclerosis might also cause anxiety symptoms. However, MRI-derived total brain volume as well as white matter lesion load was not associated with anxiety levels in multiple sclerosis in early association studies [11, 12]. More recent evidence from smaller scope studies suggests that some regional volumetric associations may exist. In particular, multiple sclerosis patients with fatigue and increased anxiety had larger caudate volumes and a thinner left parietal cortex compared to those without fatigue [13]; another study revealed that anxiety in multiple sclerosis may have a neuropathological substrate in the septo-fornical area [14]. However, the lack of a robust association between anxiety symptoms and structural MRI abnormalities may have led to the opinion that anxiety is rather a reactive response of patients facing a chronic disease.

Both functional MRI (fMRI) and EEG are valuable techniques to depict brain functional connectivity between distant brain regions. Apart from animal data [15], experimental human data derived from fMRI and EEG point towards the involvement of impaired excitability and network desynchronization in multiple sclerosis [16–18]. In particular, cognitive impairment has been linked to functional network disturbances in multiple sclerosis patients [19]. Applying EEG, it was reported that multiple sclerosis patients show an increased excitability of frontotemporal regions and decreased coherence of short and long distance connections at rest in relation to cognitive impairment [16]. Using fMRI, one study displayed enhanced regional activation within the ventrolateral prefrontal cortex (PFC) and a lack of functional connectivity between the PFC and the left amygdala in multiple sclerosis patients when exposed to emotional stimuli [20]. In addition, resting state brain networks, particularly the default mode network, have been found to be altered in several psychopathological conditions such as anxiety [21–25]. Studies combining structural and functional neuroimaging data in multiple sclerosis patients have demonstrated that thalamic atrophy is associated with disruption of cortical functional networks and is related to worse cognitive function [26–28]. However, studies investigating the neural correlates of anxiety symptoms in multiple sclerosis patients integrating structural and functional imaging approaches are surprisingly missing.

“Atrophy network mapping” is a new technique that performs seed-based functional connectivity using a normative functional connectome to determine brain regions functionally connected to atrophy patterns. This


approach has recently lent insight into the localization of neuropsychiatric symptoms in neurodegenerative disorders [29–31].

Our goal in this study was to identify anxiety-underlying network changes and their structure–function association in multiple sclerosis. Cortical atrophy maps were related to the severity of anxiety symptoms in multiple sclerosis patients and projected onto a large ( $n=1000$ ) normative resting-state functional MRI connectome. Structural equation modeling (SEM) was then applied to determine the causal relation between anxiety symptoms and the MRI volumes of the brain regions belonging to the detected functional network. To confirm our main findings, we furthermore investigated functional connectivity and cortical excitability in an additional cohort, applying transcranial magnetic stimulation and high-density electroencephalography (TMS–HD-EEG), both at rest and during an instructed threat paradigm in multiple sclerosis patients and controls [32–34].

## Methods

### Subjects

Out of a cohort of 656 multiple sclerosis patients with standardized MRIs from 2011 to 2017, 92 early clinically isolated syndrome/relapsing–remitting multiple sclerosis patients with additional anxiety measures were eligible and included in this study (Fig. 1 and Table 1). These multiple sclerosis patients [63 female, mean age  $\pm$  SD:  $34.4 \pm 9.5$  years, mean disease duration:  $1.9 \pm 3.4$  years, mean Expanded Disability Status Scale (EDSS)  $\pm$  SD:  $1.2 \pm 1.1$ ] underwent MRI twice over a study period of



**Table 1** Clinical data of the multiple sclerosis patient cohort

Demographic and clinical data	Multiple sclerosis patients (n = 92)		
Sex (female/male)	62/30		
Disease course at baseline (CIS/RRMS)	21/71		
Mean age at baseline MRI (SD) [years]	34.4 ± 9.5		
Mean age at disease onset (SD) [years]	32.5 ± 9.5		
Mean disease duration (SD) [years]	1.9 ± 3.4		
DMD (no/first line/second line) <sup>c</sup>	24/54/14		
Mean follow-up (SD) [years]	2.4 ± 1.4		
Mean EDSS score (SD)	1.2 ± 1.1		
Mean HADS-A score (SD) after 2 years	5.5 ± 4.1		
Volumetric analysis	Baseline	Follow-up	p value
Mean GM volume (SD) [ml]	632 ± 629	614 ± 607	0.001 <sup>a</sup>
Mean TB volume (SD) [ml]	1441 ± 1411	1436 ± 1411	0.008 <sup>a</sup>
Median T2 WM lesion volume (range) [ml]	1.5 (0.1–83.2)	2.0 (0.1–124.3)	0.001 <sup>b</sup>

Demographic and clinical data as well as brain volumetric measurements of early-stage multiple sclerosis patients at baseline MR scan and after follow-up

CIS clinically isolated syndrome, RRMS relapsing–remitting multiple sclerosis, SD standard deviation, EDSS Expanded Disability Status Scale, GM grey matter, TB total brain, DMD disease-modifying drugs, HADS-A Hospital Anxiety and Depression Scale-Anxiety subscale

<sup>a</sup> p values derived from paired t test

<sup>b</sup> p values derived from Wilcoxon signed-rank test

<sup>c</sup> First line: glatiramer acetate, interferon-beta, teriflunomide, dimethyl fumarate; second line: natalizumab, fingolimod, alemtuzumab

2 years (mean follow-up time ± SD: 2.4 ± 1.4 years). In addition, patients were clinically assessed in our outpatient clinic by an experienced neurologist to determine the EDSS score. The EDSS is a clinician-administered assessment scale evaluating the functional systems of the central nervous system [35]. EDSS scores were assessed 30 days after a relapse onset. For inclusion in our study, the EDSS had to be below 3.0 and the disease duration less than 5 years. These thresholds were chosen to guarantee a mildly affected multiple sclerosis cohort without considerable motor impairment. Moreover, clinical relapses and radiological disease activity [to establish “no evidence of disease activity” (NEDA-3)] were assessed. The self-administered anxiety score Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A), which is a tool used to screen for the presence of anxiety [36, 37], was determined after 2 years. The questionnaire was filled out by the patient and returned to the clinician.

Moreover, 18 additional patients with relapsing–remitting multiple sclerosis (10 female, mean age ± SD: 36.8 ± 9.4 years, mean disease duration 3.9 ± 5.0 years, mean EDSS ± SD: 2.2 ± 1.4) and 18 healthy controls (9 female, mean age: 36.0 ± 9.0 years) were selected to participate in a TMS–HD-EEG study at rest and under task in addition to the HADS-A assessment and structural MRI acquisition (Additional file 1: Table S1).

Resting-state fMRI data from 1000 healthy individuals (58% female, age range between 19 and 35 years;

mean age 21.5 years) freely available from the normative database of the Brain Genomics Superstruct Project (GSP) [38] were used to link atrophy to a common brain network (see below).

The local ethics committee of the medical faculty of the Johannes Gutenberg University Mainz (Mainz, Germany) approved the study protocol, which is according to the Declaration of Helsinki; all participants provided written informed consent.


#### MRI data acquisition

Structural MRI was performed on a 3-T MRI scanner (Magnetom Tim Trio, Siemens, Germany) with a 32-channel receive-only head coil. In all patients, imaging was performed using a sagittal 3D T1-weighted magnetization-prepared rapid gradient echo (MP-RAGE) sequence (TE/TI/TR = 2.52/900/1900 ms, flip angle = 9°, field of view = 256 × 256 mm<sup>2</sup>, matrix size = 256 × 256, slab thickness = 192 mm, voxel size = 1 × 1 × 1 mm<sup>3</sup>) and a sagittal 3D T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence (TE/TI/TR = 388/1800/5000 ms, echo-train length = 848, field of view = 256 × 256 mm<sup>2</sup>, matrix size = 256 × 256, slab thickness = 192 mm, voxel size = 1 × 1 × 1 mm<sup>3</sup>). Major anatomical abnormalities were excluded by a clinician scientist blinded to the patient data based on the subject’s T1-weighted and FLAIR images of the whole brain.

**MRI preprocessing**

MRI T1 images from all multiple sclerosis patients were preprocessed using FreeSurfer (v6.0; <http://surfer.nmr.mgh.harvard.edu>). In brief, the pipeline includes the removal of non-brain tissue and intensity normalization, followed by subcortical segmentation and cortical surface reconstruction via tessellation of the grey matter (GM)/white matter (WM) and GM/CSF boundaries, accompanied by automated topology correction with accurate surface deformation to identify tissue borders (Fig. 2A).

Cortical thickness was then calculated as the distance between the WM and GM surfaces at each point (vertex) of the reconstructed cortical mantle [39]. Individual results were visually inspected to ensure accuracy of the surface creation. Errors in the surface reconstruction were manually corrected to improve the cortical thickness estimation. Given the longitudinal nature of the study, the resulting cross-sectional preprocessed data was then used to create a mean single-subject template, to which each time-point image was rigidly transformed.



**Fig. 2** **A** Longitudinal cortical thickness analysis. Workflow for longitudinal MRI morphometric analysis. **B** Anxiety-related atrophy maps across multiple sclerosis patients. Atrophy of the left PFC (peak region: rostral middle frontal lobe) was associated with anxiety scores measured by the HADS-A scale. **C** Atrophy network mapping. Generated atrophy maps are used in a seed-based functional connectivity analysis in a large dataset of healthy controls to find functionally connected regions. The atrophy network mapping approach identified the PFC, amygdala and hippocampus as brain regions functionally connected to the previously detected atrophied location

This final space transformation further reduces inter-individual variability and permits an implicit vertex correspondence across all time points [40]. After preprocessing, mean cortical thickness based on the Desikan–Killiany atlas [41] and mean subcortical volumes [42] were obtained for each region. From cortical thickness values, individual maps of cortical atrophy (annual atrophy, expressed in  $\text{mm}^3$  per year) were defined as:  $\text{atrophy} = (\text{CT}_{\text{Follow-up}} - \text{CT}_{\text{Baseline}}) / (\text{MRI time } \Delta)$ . The  $\text{CT}_{\text{Baseline}}$  and  $\text{CT}_{\text{Follow-up}}$  are the estimated cortical thickness maps at each time point, and “MRI time  $\Delta$ ” is the individual delay between the two MRI scans in years. The same procedure was used to calculate atrophy of subcortical volumes.

### Functional MRI data and preprocessing

Normative resting-state fMRI data from the 1000 healthy subjects were acquired at Harvard Medical School and Massachusetts General Hospital and are part of the publicly available GSP dataset [38]. These fMRI data were obtained with a 3-T Tim Trio scanner (Siemens Healthcare, Erlangen, Germany) MRI using a 12-channel receive coil array scanner.

Resting-state fMRI data was acquired at 3 mm isotropic resolution with  $\text{TR} = 3000$  ms and 124 frames. fMRI data preprocessing included (1) removal of the first five frames, (2) motion correction using rigid body translation and rotation, (3) slice timing correction, (4) alignment with structural image, (5) normalization to Montreal Neurological Institute (MNI) space using the deformation matrices obtained during MRI preprocessing with the CAT12 toolbox (Structural Brain Mapping group, Jena University Hospital, Jena, Germany), (6) smoothing by a 6 mm full-width half-maximum (FWHM) kernel, (7) nuisance covariate regression (including six motion correction parameters, and averaged WM and CSF signals), and (8) bandpass filtering (between 0.01 and 0.08 Hz). WM and CSF masks were obtained from segmentation of the anatomical T1 image, followed by binarizing the probabilistic tissue maps at a threshold of 0.9 and 0.7, respectively. All preprocessing steps were carried out following recommended guidelines using SPM12 [43].

### Atrophy network mapping

For the multiple sclerosis cohort, we derived a “functional network map”—defined as brain regions functionally connected to the previously generated anxiety-related atrophy map [30, 31]. To this end, we used FreeSurfer (v6.0; <http://surfer.nmr.mgh.harvard.edu>) to determine, in a vertex-wise fashion, in which specific cortical regions multiple sclerosis patients present a correlation between cortical thinning (atrophy) over 2 years and anxiety severity ( $p < 0.05$ , controlling for multiple comparisons with

Monte Carlo simulations). The resulting cluster, localized in the dorsal PFC, was then binarized and entered as seed to compute resting-state functional connectivity on a normative dataset [38]. Using the GSP normative dataset, we measured average blood–oxygen–level–dependent (BOLD) time courses within the seed corresponding to the anxiety-related atrophy map and correlated these values with the BOLD time course at every other brain voxel [30, 31]. This seed-based functional connectivity method is similar to lesion network mapping; the only difference is that instead of a brain lesion, the resulting atrophy map is used as a seed [44, 45]. Functional connectivity was determined by calculating the correlation between the mean time courses of the atrophied region of interest (ROI) and all other brain voxels in each of the 1000 images [45, 46]. The correlation values were then transformed to  $z$  values using the Fisher’s transform and used to compute a voxel-wise  $t$ -distribution that was finally thresholded at a voxel-wise family-wise error (FWE)-corrected value ( $p = 0.05$ ). The connectivity maps were created in MNI space with  $1.5 \times 1.5 \times 1.5$  mm voxel size.

### Instructed threat paradigm

Before starting this investigation, participants were informed that one visual cue (circle) is associated with a mild electric shock with a probability of 33%, while the other visual cue (square) is safe. The intensity of the electric shock was calibrated for each subject, such that stimulation was highly fearful [minimum of seven on a scale of 0 (not fearful) to 10 (highly fearful)] [47]. The instructed threat paradigm (Fig. 4A) encompassed presenting on a computer screen the visual cue (circle or square) that denoted the anticipated condition (threat or safe). One second after every visual cue onset, a neuronavigated single-pulse TMS was applied on the right dorsomedial PFC. The stimulation intensity was 110% of resting-state motor threshold (RMT), as previously described [33]. Each trial consisted of presenting the visual cue on the screen for 5 s followed by a fixation cross on the center of the screen that jittered between 5 and 6 s. During the threat condition, electric shocks were applied to the dorsal part of the left hand with a probability of 33% with an electric stimulator (DS7A, Digitimer, USA) at any moment while the visual threat cue was present on the screen. In total, the paradigm consisted of 90 trials and lasted for 15 min. Continuous EEG recordings were performed in all participants for the complete duration of the paradigm. Furthermore, continuous resting-state EEG data was acquired in all participants for 5 min prior to the instructed threat paradigm, during which the participants were asked to sit still and think of nothing. The EEG data was acquired with a high-density (HD) 256 channel EEG system (Net Station 5.0, EGI, USA)

operating at a sampling frequency of 250 Hz and electrode impedances below 50 k $\Omega$  [48].

### HD-EEG data processing

The processing steps for HD-EEG data (Fig. 3A) were conducted in MATLAB R2015B (Mathworks, USA) using in-house customized analysis scripts and the open-source MATLAB toolbox Fieldtrip [49]. The continuous HD-EEG data acquired during the instructed threat paradigm was divided into epochs from  $-2$  to  $+5$  s relative to visual cue onset. Afterwards, the HD-EEG data from 0.005 s prior to and 0.02 s after the TMS pulse, which contained the TMS pulse itself and ringing artifacts, was removed. In addition, in all participants the trials in which electric shocks were administered were removed from further analysis. Then, HD-EEG data was re-referenced to a grand average of all electrodes. HD-EEG data was visually inspected and noisy trials were discarded. Subsequently, independent component analysis (ICA) was implemented and the components related to the physiological (eye blinks and muscle) and TMS (decay) artifacts were removed [50]. Finally, the remaining ICA components were transformed back into electrode data representation. The full description of the processing


steps performed for resting-state HD-EEG data are described elsewhere [51]. Briefly, the continuous HD-EEG data was segmented into 2 s epochs after discarding the artifactual signals identified by visual inspection and ICA analysis. Afterwards, the source and connectivity analyses based on the power were performed in theta (4–7 Hz) and gamma (30–70 Hz) frequency bands.

### Heart rate estimation

The heart rate was extracted from the HD-EEG signals (Additional file 1: Fig. S1) using the extended version of the ICA algorithm, based on the information maximization [52] as previously reported [33].

### Source and connectivity analyses

The source analysis was conducted with the beamformer approach called dynamic imaging of coherent sources (DICS) for both resting state and instructed threat paradigm data in the theta and gamma frequency bands. The complete description of the analysis has been given elsewhere [53]. In brief, to determine the origin of HD-EEG activity in a specific frequency band observed over the scalp electrodes, both the forward problems and inverse problems need to be addressed. In this study, the lead-field matrix was modeled with the finite element method [54]. The DICS analysis was applied to extract the pooled source signals from three brain regions, namely right dorsomedial PFC, right amygdala and right hippocampus. These anatomical brain regions were defined according to our previous publication [33]. Finally, the connectivity fingerprints were extracted using the temporal partial directed coherence method (TPDC). The detailed description of the TPDC method has been previously described [54]. After estimating the TPDC values, the significance level was calculated from the applied data using a bootstrapping method [55]. In short, we divide the original time series into smaller non-overlapping windows and randomly shuffle the order of these windows to create a new time series. The MVAR (multivariate autoregressive) model is fitted to the shuffled time series and TPDC is estimated. The bootstrapping is performed 1000 times and the average TPDC value is taken as the significance threshold for all connections. The TPDC values were averaged across time [54]. This process is performed separately for each participant. In this study, the open-source MATLAB package autoregressive fit (ARFIT) [56, 57] was used for estimating the autoregressive coefficients from the spatially filtered source signals of the identified brain regions. We applied the time reversal technique [58] as a second significance test on the connections already identified by TPDC using a data-driven bootstrapping surrogate significance test.



### Structural equation modeling

SEM is an analytical tool used to determine causal relationships between variables in a model-based approach [59]. Here, the SEM analysis was performed using the SEM toolbox for MATLAB (<https://www.mathworks.com/matlabcentral/fileexchange/60013-toolbox-for-structural-equation-modelling-sem>) to assess the relationship between brain volumes (PFC, amygdala and hippocampus) and HADS-A score after 2 years.

We employed the maximum-likelihood method of estimation to fit the models. In order to adjust the models for a large sample size, we used the root mean square error of approximation (RMSEA) index, which improves precision without increasing bias [60]. The RMSEA index estimates lack of fit in a model compared to a perfect model and therefore should be low. Here, the RMSEA index for all models was below 0.05, implying a very good fit. In all models, the invariant under a constant scaling (ICS) and ICS factor criteria were close to zero, indicating that models were appropriate for analysis. Finally, using the Akaike information criterion (AIC) the quality of each model relative to other models was estimated, with smaller values signifying a better fit of the model. The obtained AIC comparing the models varied between 0.01 and 0.03 (good fit of the models). The strength of associations between the variables in the models was quantified by standardized coefficients ( $s$ ), ranging from 0 (no association) to 1 (very strong association).

### Statistical analysis

The statistical analyses were performed with MATLAB R2015B and SPSS 23.0 (IBM, Armonk, NY, USA).

Vertex-wise regression analyses testing the association between cortical atrophy over 2 years with anxiety were assessed under the general linear model while adjusting for age and sex. Control for multiple comparisons was performed using Monte Carlo simulations ( $n=1000$ ,  $p<0.05$ ).  $P$  values  $<0.05$  were considered statistically significant.

To examine the significant differences in TPDC, two-tailed Student's  $t$ -tests were performed. We performed a two-factorial ANOVA (groups, connections) for the TMS-HD-EEG connectivity analysis, separately for theta and gamma bands. Significant differences in oscillatory power were tested using nonparametric cluster-based statistics with the Monte-Carlo method in theta and gamma frequency bands [61].

## Results

### Cortical atrophy linked to anxiety symptoms

In order to identify anxiety-related regional changes in GM integrity, we investigated regional cortical and sub-cortical atrophy in a cohort of early multiple sclerosis

patients over 2 years (Additional file 1: Tables S2 and S3) and anxiety symptoms assessed by the HADS-A scale (Fig. 1). Longitudinal cortical thickness analysis revealed widespread cortical thinning over the observation period in both hemispheres [left:  $t(91)=4.4$ ,  $p<0.001$ ; right:  $t(91)=3.6$ ,  $p=0.001$ ]. In the age- and sex-adjusted correlation analysis with the HADS-A score, we detected one prominent cluster: the left rostral middle frontal lobe, as part of the dorsal PFC was associated with HADS-A ( $r=0.214$ ;  $p=0.040$ ) (Fig. 2B, Additional file 1: Tables S4 and S5).

HADS-A scores in patients who developed a clinical relapse, EDSS-relevant progression or MRI activity ( $n=57$  patients, mean  $\pm$  SD HADS-A score after 2 years =  $5.2 \pm 4.1$ ) did not differ (independent Student's  $t$  test:  $p=0.441$ ) from those patients who remained relapse free ( $n=35$  patients with NEDA-3, HADS-A score after 2 years =  $5.9 \pm 4.1$ ).

### Anxiety-related atrophy network mapping

We hypothesized that anxiety-related cortical atrophy in multiple sclerosis patients would localize to a functional brain network. Hence, we applied a novel technique called atrophy network mapping to determine the brain regions functionally connected to the location of anxiety-related atrophy. Thus, binarized atrophy maps from the prior correlation analysis were used as seed points in functional connectivity analysis in a large ( $n=1000$ ) normative dataset. The resulting atrophy network map unveiled a specific network connectivity pattern (Fig. 2C) (statistical threshold  $T > \pm 15$ , corresponding to whole brain FWE-corrected  $p < 10^{-12}$ ) consisting of the ipsilateral PFC, but strikingly also the contralateral PFC and both amygdala and hippocampus. The functional network of other cortical or subcortical regions (e.g., basal ganglia) was not connected to the previously generated atrophy map.

### PFC, amygdala and hippocampus volumes predict anxiety symptoms

We next applied SEM to assess whether baseline volumes of the regions within the identified functional network, namely the PFC, amygdala and hippocampus, predict the severity of anxiety symptoms. The obtained fit indices in the SEM analysis implied a good fit of the constructed models to the observed data, providing robust relations between the variables. SEM revealed that the volumes of all three structures predict anxiety symptoms after 2 years in the 92 multiple sclerosis patients (Table 2). SEM with resultant standardized coefficients ( $s$ ) identified the left amygdala ( $s=0.852$ ,  $p=0.001$ ) and the left hippocampus ( $s=0.836$ ,  $p=0.002$ ) as the strongest prognostic factors for anxiety severity 2 years after the initial

**Table 2** Brain volumes and their capability in predicting anxiety through SEM

Anxiety-related brain structures	Anxiety (HADS-A) after 2 years ( <i>n</i> = 92 patients)		Anxiety (HADS-A) within the TMS–HD-EEG cohort ( <i>n</i> = 18 patients)	
	<i>s</i>	<i>p</i> value	<i>s</i>	<i>p</i> value
Amygdala (left)	0.852	0.001	0.886	0.001
Amygdala (right)	0.825	0.004	0.803	0.003
Hippocampus (left)	0.836	0.002	0.858	0.002
Hippocampus (right)	0.816	0.006	0.782	0.003
Prefrontal cortex (left)	0.675	0.007	0.604	0.010
Prefrontal cortex (right)	0.633	0.011	0.704	0.006

Association between brain volumes of the regions within the identified functional network and HADS-A score in the main cohort and the TMS–HD-EEG cohort. The predictive power is expressed as SEM-derived standardized coefficient (*s*)


HADS-A Hospital Anxiety and Depression Scale-Anxiety subscale, TMS–HD-EEG transcranial magnetic stimulation and high-density EEG, SEM structural equation modeling

MRI. The volumes of the PFC, amygdala and hippocampus derived from the cohort of multiple sclerosis patients who later underwent TMS–HD-EEG showed similar predictive powers for predicting anxiety symptoms (Table 2).

**Reduced connectivity between PFC and amygdala in multiple sclerosis**

To explore if the identified functional network from the atrophy network mapping approach is disturbed in multiple sclerosis patients, we investigated a cohort of 18 multiple sclerosis patients and 18 age-matched healthy controls in a TMS–HD-EEG experiment (Additional file 1: Table S1). Here, we first examined the effective connectivity between PFC, amygdala and hippocampus (Figs. 3 and 4) due to the results of the prior functional connectivity analysis findings in the main cohort. Strikingly, HD-EEG revealed differences in the theta and gamma frequency bands between the two groups for hippocampus–PFC, hippocampus–amygdala and PFC–amygdala connections at rest (Table 3, Additional file 1: Fig. S2A) and during task/threat paradigm (Table 3, Additional file 1: Fig. S2B, *p* < 0.01, two-sided *t* test).

Effective connectivity at rest between these three regions was different in multiple sclerosis patients as compared to healthy controls (Fig. 3). For the theta band, both the factor “group” [*F* (1, 244) = 268.82; *p* < 0.0001] and the factor “connection” [*F* (5, 244) = 14.42; *p* < 0.0001] significantly contributed to these alterations. The same was also true for the gamma band [factor “group”: *F* (1,



**Fig. 4** Altered cortical excitability in multiple sclerosis in response to threat. TMS–HD-EEG was performed in a second patient cohort (*n* = 18) and compared to healthy controls (*n* = 18). **A** Threat paradigm with a 33% chance of receiving a shock after appearance of a circle displayed on a monitor. A TMS pulse was applied 1 s after cue onset. HD-EEG (256 electrodes) was performed simultaneously. **B** Multiple sclerosis versus control showed an increased theta power at rest in prefrontal regions following TMS stimulation of the dorsal PFC; under threat, multiple sclerosis patients displayed a reduced theta and gamma power

245) = 1029.9; *p* < 0.0001 and factor “connection”: *F* (4, 245) = 10.28; *p* < 0.0001]. All post hoc analyses were significant (*p* < 0.0001). Whereas the connectivity from hippocampus to PFC and amygdala was intact, we found a reduced connectivity between PFC and amygdala for the theta and gamma bands (*p* < 0.0001) (Fig. 3B) in multiple sclerosis patients. On the other hand, we found an increased information flow in the theta band in multiple sclerosis patients from hippocampus to PFC (*p* < 0.0001) possibly accounting for a compensatory mechanism. For the theta band, effective connectivity positively correlated with the PFC, amygdala and hippocampus volumes indicating in reverse that worse connectivity was associated with reduced volumes of these regions (Additional file 1: Table S6).

**Increased excitability in the PFC at rest**

In order to investigate the potential pathophysiological cause underlying this disrupted information flow between the structures of the anxiety-related



**Table 3** Coherence

Coherence	MS patients	Healthy controls	<i>p</i> value <sup>a</sup>
Theta (rest) HIP–PFC	0.33 ± 0.006	0.38 ± 0.05	0.0001
Gamma (rest) HIP–PFC	0.39 ± 0.04	0.22 ± 0.04	< 0.0001
Theta (after threat) HIP–PFC	0.41 ± 0.04	0.48 ± 0.05	0.0057
Gamma (after threat) HIP–PFC	0.32 ± 0.06	0.47 ± 0.04	0.0032
Theta (rest) HIP–AMG	0.39 ± 0.02	0.40 ± 0.05	0.132
Gamma (rest) HIP–AMG	0.45 ± 0.03	0.37 ± 0.02	< 0.0001
Theta (after threat) HIP–AMG	0.39 ± 0.05	0.50 ± 0.05	< 0.0001
Gamma (after threat) HIP–AMG	0.41 ± 0.03	0.29 ± 0.06	< 0.0001
Theta (at rest) PFC–AMG	0.40 ± 0.02	0.39 ± 0.03	0.234
Gamma (at rest) PFC–AMG	0.35 ± 0.03	0.44 ± 0.03	< 0.0001
Theta (after threat) PFC–AMG	0.42 ± 0.04	0.31 ± 0.01	< 0.0001
Gamma (after threat) PFC–AMG	0.22 ± 0.05	0.37 ± 0.04	< 0.0001

Coherence between prefrontal cortex, amygdala and hippocampus at rest and during threat processing in the TMS–HD-EEG study according to Additional file 1: Fig S2. The coherence is expressed as mean ± standard deviation

PFC prefrontal cortex, HIP hippocampus, AMG amygdala

<sup>a</sup> *P* values derived from two-tailed Student's *t* test

network, we assessed the HD-EEG power (hereinafter termed excitability) following a TMS pulse during an instructed threat paradigm. At rest, multiple sclerosis patients showed increased excitability compared to controls, evidenced as higher theta power in prefrontal electrodes after the TMS pulse at the dorsal PFC (Fig. 4B,  $p < 0.05$ , two-sided *t* test, 32 electrodes). This increase in the excitability was seen in the ipsilateral and contralateral PFC and detected up to 400 ms after the TMS stimulation.

Under threat condition, we found a decreased excitability (i.e. decreased theta power) (Fig. 4B,  $p < 0.05$ , two-sided *t* test, 45 electrodes) in the dorsal PFC, both after cue onset (0.15 s until 0.45 s) and after the TMS pulse (1.15 s until 1.45 s) in multiple sclerosis patients. These effects were seen during threat processing on both sides. Moreover, we observed a decreased gamma power for parieto-temporal electrodes in multiple sclerosis patients under threat condition (Fig. 4B,  $p < 0.05$ , two-sided *t* test, 26 electrodes). During the threat paradigm (Fig. 4A), the heart rate measured by beats per minute (bpm) of both multiple sclerosis patients (no threat: 73 ± 1.8 bpm; threat: 82 ± 1.5 bpm) and healthy controls (no threat: 72 ± 1.3 bpm; threat: 84 ± 1.6 bpm) increased (Additional file 1: Fig. S1,  $p < 0.05$ , two-sided

*t* test), which served as a positive physiological control for our paradigm.

## Discussion

Our study provides evidence for functional network alterations underlying anxiety symptoms in multiple sclerosis. Using atrophy network mapping we identified a specific functional connectivity network consisting of the ipsi- and contralateral PFC as well as the amygdala and hippocampus. These brain areas are known to be essentially involved in emotion regulation in humans [62]. Structural equation modeling confirmed that the volumes of the PFC, amygdala and hippocampus were significant determinants that influence anxiety symptoms in multiple sclerosis. In a subsequent TMS–HD-EEG study, we found an impaired effective connectivity between the PFC and amygdala at rest in multiple sclerosis patients compared to healthy subjects. The underlying cause of this network disruption might be explained by an altered cortical excitability since we observed an increased excitability in prefrontal cortical regions in multiple sclerosis patients compared to controls at rest. Under threat, the PFC conversely showed a decreased excitability response in patients as compared to controls. Thus, altered neural excitability may underlie the observed disconnected network and may likewise underlie anxiety behavior as pathophysiological substrate [15].

## Structural correlates of multiple sclerosis-related anxiety

Structural and functional alterations of the PFC, amygdala and hippocampus have been reported in patients with anxiety disorders [63–70]. In contrast, structural or functional MRI correlates of anxiety symptoms in multiple sclerosis patients are still inconclusive, reflecting the complexity of the disease and challenges of available imaging technology [71, 72]. Whereas some early studies investigating multiple sclerosis-related anxiety showed no correlation with total lesion load or total brain volume [11, 12], recent advances in the imaging field now revealed an association of distinct regional lesion load measurements with anxiety [14, 73].

This ambiguity still leads to the notion that anxiety might be a reactive response following chronic disease progression (e.g., ongoing motor impairment) [11]. As a result of this, anxiety in multiple sclerosis is often classified as a mere comorbid condition [71]. However, our study provides evidence that anxiety symptoms in multiple sclerosis patients might be directly linked to its pathology, as patients scoring high on the HADS-A specifically exhibited increased atrophy in the PFC—a crucial area for top-down control for threat and emotional processing [32]. Although the official diagnosis of

a generalized anxiety disorder according to the International Classification of Diseases would require a detailed personal interview, the HADS-A accurately identifies the presence of anxiety symptoms in multiple sclerosis. Moreover, the HADS-A has the highest sensitivity (82%) for detecting anxiety symptoms as compared to other anxiety scales in people with multiple sclerosis [74]. Notably, anxiety scores in our multiple sclerosis cohort were independent of relapse activity indicating that acute inflammatory activity was no confounder in the present study.

In a large meta-analysis of patients with various anxiety disorders, only atrophy of the anterior cingulate and inferior frontal cortex was associated with anxiety symptoms compared to healthy controls [69]. The anterior cingulate cortex is strongly connected with the PFC, a region that was identified in our study as being related to anxiety severity in multiple sclerosis. In addition, atrophy of the ventromedial PFC, a region associated with emotion and reward in decision-making, has been demonstrated in patients with generalized anxiety disorders [75]. Physiologically, activation of the medial PFC is associated with positive emotion, which can serve to regulate and diminish negative emotion [76]. In line with these results, our hypothesis is that the cortical thinning of the dorsal PFC in our study leads to impaired emotional processing, triggered by a network disruption that may increase the vulnerability for anxiety-related symptoms in multiple sclerosis.

#### **Networks related to anxiety in patients with multiple sclerosis**

We observed a correlation between 2-year cortical thinning and anxiety severity solely in the left dorsal PFC. The peak region of anxiety-related cortical atrophy across multiple sclerosis patients was used as a seed location for functional connectivity analysis in normal healthy individuals [30]. This allowed us to identify a brain network functionally connected to atrophied locations [77]. The detected left-lateralized atrophy of the dorsal PFC was related to a network comprising the bilateral PFC, and—with the largest effects—the amygdala and hippocampus. Notably, these brain regions all play a prevailing role in processing threat and anxiety [63] and belong to the limbic system where subcortical structures meet the cerebral cortex [78].

The here identified anxiety-related network results in multiple sclerosis patients resemble previously observed patterns of network-level dysfunction described for generalized anxiety disorders [79]. The atrophy of the PFC, and hence the loss of structural cortical integrity, presumably alters the functional connectivity to specific

brain areas (in this case, amygdala and hippocampus) distal from the primary spot of atrophy depicting the loss of information input from a damaged part of the brain [80].

Interestingly, in a recent meta-analysis including structural and functional MRI studies in generalized anxiety disorders, a reduced functional connectivity between PFC and amygdala was observed resulting from tasks investigating emotion dysregulation [67, 68]. Our fMRI and HD-EEG data acquired in multiple sclerosis patients supports this observation. The resulting impaired effective connectivity between the PFC and amygdala in our study is well in line with findings in anxiety development during adolescence [64] and is a replicated phenomenon in both the generation and regulation of emotions [65]. Furthermore, dysregulated prefrontal control over amygdala is engaged in the pathogenesis of anxiety disorders [66]. Here, we demonstrate in multiple sclerosis patients that through focal PFC atrophy the prefrontal control seems to become defective, resulting in aberrant amygdala activation and deficits in threat processing.

Additional evidence for the structure–function association between PFC, amygdala and hippocampus with anxiety development in multiple sclerosis was acquired by SEM. This predictive modeling is appropriate for employing complex models to evaluate hypothesized causal associations. The MRI volumes of all brain regions belonging to the detected functional network (PFC, amygdala and hippocampus) were associated with anxiety symptoms in multiple sclerosis. Interestingly, amygdala and hippocampus volumes of the left hemisphere showed a slightly higher predictive power than those of the right. This observation may prompt further investigations to address the issue of a possible lateralized involvement of these volumes implicated in limbic emotional circuits associated with anxiety.

#### **Network excitability at rest and during threat processing**

Increased excitability of the PFC at rest as found here by TMS–HD-EEG, represents a compensatory mechanism for preservation of function (i.e. motor control) and is possibly due to locally reinforcing circuits [81]. Decreased excitability in the PFC upon threat in multiple sclerosis, however, indicates an impaired cortical processing under a stimulus, knowing that the PFC is normally activated during threat in healthy people [82]. In addition, we demonstrated that the effective connectivity from the PFC to the amygdala was specifically impaired in multiple sclerosis as compared to controls. These results provide evidence for a disturbed inhibitory role of the PFC on amygdala threat response in multiple sclerosis patients.

Therapeutically, repetitive TMS or transcranial direct current stimulation could be used to modulate brain

networks through periodic treatments of preselected target areas. In fact, there are studies for multiple sclerosis using transcranial direct current stimulation to improve non-motor functions, such as fatigue [83–85] or cognition [86] with mild to moderate effects. These findings all support the involvement of impaired network synchronization in the disease pathology. In a recent study, impaired memory performance in multiple sclerosis patients was instantly restored via rebalancing impaired connectivity and excitability through targeted neuromodulation of the affected networks achieved by direct current or repetitive TMS of the dorsal PFC [18]. The latter strengthens our hypothesis that specific symptoms like anxiety can be referred to specific pathologic areas giving rise to functional network changes and thus be treated by normalizing the synchronization of brain oscillatory networks in multiple sclerosis.

## Conclusions

Our findings suggest that local anxiety-related structural changes in multiple sclerosis functionally spread beyond the sites of initial injury into widely interconnected areas and target a specific large-scale functional network that resembles known neurobiological anxiety circuits involving the PFC, amygdala and hippocampus. The here identified potential biological basis of anxiety in multiple sclerosis patients represents an opportunity for novel treatment approaches aiming to modulate brain networks in multiple sclerosis.

## Abbreviations

AIC: Akaike information criterion; BOLD: Blood–oxygen-level-dependent; DICS: Dynamic imaging of coherent sources; EDSS: Expanded Disability Status Scale; FLAIR: Fluid-attenuated inversion recovery; fMRI: Functional MRI; FEW: Family-wise error; FWHM: Full-width half-maximum; GM: Grey matter; GSP: Brain Genomics Superstruct Project; HADS-A: Hospital Anxiety and Depression Scale-Anxiety subscale; HD: High density; ICA: Independent component analysis; ICS: Invariant under a constant scaling; MNI: Montreal Neurological Institute; MP-RAGE: Magnetization-prepared rapid gradient echo; NEDA-3: No evidence of disease activity; PFC: Prefrontal cortex; RMSEA: Root mean square error of approximation; RMT: Resting-state motor threshold; ROI: Region of interest; SEM: Structural equation modeling; TMS–HD-EEG: Transcranial magnetic stimulation and high-density EEG; TPDC: Temporal partial directed coherence method; WM: White matter.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12974-022-02476-0>.

**Additional file 1: Table S1.** Clinical data of the additional multiple sclerosis patients in the TMS–HD-EEG study. **Table S2.** Cortical volume changes over 2 years (ROI-wise). **Table S3.** Subcortical volume changes over 2 years. **Table S4.** Association between cortical atrophy over 2 years and HADS-A (anxiety) after 2 years. **Table S5.** Association between subcortical atrophy over 2 years and HADS-A (anxiety) after 2 years. **Table S6.**

Correlations ( $r$ ) between connectivity strength and volumes (prefrontal cortex, hippocampus and amygdala). **Figure S1.** Heart rate of multiple sclerosis patients and healthy controls during TMS–HD-EEG study. **Figure S2.** Connectivity/coherence. Connectivity and coherence between prefrontal cortex, amygdala and hippocampus at rest and during threat processing in the TMS–HD-EEG study.

## Acknowledgements

The authors thank Cheryl Ernest for proofreading and editing the manuscript.

## Author contributions

EE, MM, GEG, VCC acquired and analyzed the data and initial interpretation and wrote the first draft of the manuscript. FL, SB, FZ discussed the results and helped in interpretation and revising the manuscript. SG, VF acquired funding and major contributors in writing the manuscript. All authors read and approved the final manuscript.

## Funding

Open Access funding enabled and organized by Projekt DEAL. This work was supported by the German Research Foundation (DFG; CRC-TR-128).

## Availability of data and codes

The data and algorithms essential to the conclusions of this study are available from the corresponding author upon reasonable request.

## Declarations

### Ethics approval and consent to participate

The local ethics committee of the medical faculty of the Johannes Gutenberg University Mainz (Mainz, Germany) approved the study protocol, which is according to the Declaration of Helsinki; all participants provided written informed consent.

### Consent for publication

Not applicable.

### Competing interests

Stefan Bittner has recently received consultation funds from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme and Roche. Frauke Zipp has recently received research grants and/or consultation funds from the DFG, BMBF, PMSA, Genzyme, Janssen, Merck Serono, Roche, Novartis, Celgene, Sanofi-Aventis. The other authors report no relevant competing interests.

### Author details

<sup>1</sup>Department of Neurology, Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany. <sup>2</sup>Biomedical Statistics and Multimodal Signal Processing Unit, Department of Neurology, Focus Program Translational Neuroscience (FTN) Neuroimaging Center, Rhine Main Neuroscience Network (rmn2), University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. <sup>3</sup>Section of Movement Disorders and Neurostimulation, Department of Neurology, Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.

Received: 25 July 2021 Accepted: 15 May 2022

Published online: 24 May 2022

## References

- Calabrese P, Penner IK. Cognitive dysfunctions in multiple sclerosis—a “multiple disconnection syndrome”? *J Neurol*. 2007;254(Suppl 2):18–21.
- Murphy R, O’Donoghue S, Counihan T, McDonald C, Calabresi PA, Ahmed MA, et al. Neuropsychiatric syndromes of multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2017;88(8):697–708.

3. Caceres F, Vanotti S, Benedict RH, Group RW. Cognitive and neuropsychiatric disorders among multiple sclerosis patients from Latin America: results of the RELACCEM study. *Mult Scler Relat Disord*. 2014;3(3):335–40.
4. Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry—novel perspectives on brain disorders. *Nat Rev Neurol*. 2019;15(6):317–28.
5. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. *Mult Scler*. 2007;13(1):67–72.
6. Ribbons K, Lea R, Schofield PW, Lechner-Scott J. Anxiety levels are independently associated with cognitive performance in an Australian multiple sclerosis patient cohort. *J Neuropsychiatry Clin Neurosci*. 2017;29(2):128–34.
7. McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. *Neurology*. 2018;90(15):e1316–23.
8. Disanto G, Zecca C, MacLachlan S, Sacco R, Handunnetthi L, Meier UC, et al. Prodromal symptoms of multiple sclerosis in primary care. *Ann Neurol*. 2018;83(6):1162–73.
9. Kalron A, Aloni R, Allali G. The relationship between depression, anxiety and cognition and its paradoxical impact on falls in multiple sclerosis patients. *Mult Scler Relat Disord*. 2018;25:167–72.
10. Thomas KR, Bangen KJ, Weigand AJ, Edmonds EC, Wong CG, Cooper S, et al. Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. *Neurology*. 2020;94(4):e397–406.
11. Zorzon M, de Masi R, Nasuelli D, Ukmar M, Mucelli RP, Cazzato G, et al. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. *J Neurol*. 2001;248(5):416–21.
12. Sanfilippo MP, Benedict RH, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. *Neurology*. 2006;66(5):685–92.
13. Chalah MA, Kauv P, Creange A, Hodel J, Lefaucheur JP, Ayache SS. Neurophysiological, radiological and neuropsychological evaluation of fatigue in multiple sclerosis. *Mult Scler Relat Disord*. 2019;28:145–52.
14. Palotai M, Mike A, Cavallari M, Strammer E, Orsi G, Healy BC, et al. Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis. *Mult Scler*. 2018;24(8):1105–14.
15. Ellwardt E, Pramanik G, Luchtman D, Novkovic T, Jubal ER, Vogt J, et al. Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis. *Nat Neurosci*. 2018;21(10):1392–403.
16. Leocani L, Locatelli T, Martinelli V, Rovaris M, Falautano M, Filippi M, et al. Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. *J Neurol Neurosurg Psychiatry*. 2000;69(2):192–8.
17. Zipser CM, Premoli I, Belardinelli P, Castellanos N, Rivolta D, Heidegger T, et al. Cortical excitability and interhemispheric connectivity in early relapsing–remitting multiple sclerosis studied With TMS-EEG. *Front Neurosci*. 2018;12:393.
18. Hulst HE, Goldschmidt T, Nitsche MA, de Wit SJ, van den Heuvel OA, Barkhof F, et al. rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2017;88(5):386–94.
19. Di Filippo M, Portaccio E, Mancini A, Calabresi P. Multiple sclerosis and cognition: synaptic failure and network dysfunction. *Nat Rev Neurosci*. 2018;19(10):599–609.
20. Passamonti L, Cerasa A, Liguori M, Gioia MC, Valentino P, Nistico R, et al. Neurobiological mechanisms underlying emotional processing in relapsing–remitting multiple sclerosis. *Brain J Neurol*. 2009;132(Pt 12):3380–91.
21. Coutinho JF, Fernandes SV, Soares JM, Maia L, Goncalves OF, Sampaio A. Default mode network dissociation in depressive and anxiety states. *Brain Imaging Behav*. 2016;10(1):147–57.
22. Paul ER, Farmer M, Kampe R, Cremers HR, Hamilton JP. Functional connectivity between extrastriate body area and default mode network predicts depersonalization symptoms in major depression: findings from an a priori specified multinetwork comparison. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2019;4(7):627–35.
23. Imperatori C, Farina B, Adenzato M, Valenti EM, Murgia C, Marca GD, et al. Default mode network alterations in individuals with high-trait-anxiety: an EEG functional connectivity study. *J Affect Disord*. 2019;246:611–8.
24. Petrican R, Saverino C, Shayna Rosenbaum R, Grady C. Inter-individual differences in the experience of negative emotion predict variations in functional brain architecture. *Neuroimage*. 2015;123:80–8.
25. Bonavita S, Sacco R, Esposito S, d'Ambrosio A, Della Corte M, Corbo D, et al. Default mode network changes in multiple sclerosis: a link between depression and cognitive impairment? *Eur J Neurol*. 2017;24(1):27–36.
26. Tewarie P, Schoonheim MM, Stam CJ, van der Meer ML, van Dijk BW, Barkhof F, et al. Cognitive and clinical dysfunction, altered MEG resting-state networks and thalamic atrophy in multiple sclerosis. *PLoS ONE*. 2013;8(7):e69318.
27. Tewarie P, Schoonheim MM, Schouten DI, Polman CH, Balk LJ, Uitdehaag BM, et al. Functional brain networks: linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study. *Hum Brain Mapp*. 2015;36(2):603–18.
28. Deppe M, Kramer J, Tenberge JG, Marinell J, Schwindt W, Deppe K, et al. Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis. *Hum Brain Mapp*. 2016;37(5):1866–79.
29. Fox MD. Mapping symptoms to brain networks with the human connectome. *N Engl J Med*. 2018;379(23):2237–45.
30. Tetreault AM, Phan T, Orlando D, Lyu I, Kang H, Landman B, et al. Network localization of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer's disease. *Brain J Neurol*. 2020;143(4):1249–60.
31. Tetreault AM, Phan T, Petersen KJ, Claassen DO, Neth BJ, Graff-Radford J, et al. Network localization of alien limb in patients with corticobasal syndrome. *Ann Neurol*. 2020;88(6):1118–31.
32. Etkin A, Egner T, Kalisch R. Emotional processing in anterior cingulate and medial prefrontal cortex. *Trends Cogn Sci*. 2011;15(2):85–93.
33. Gonzalez-Escamilla G, Chirumamilla VC, Meyer B, Bonertz T, von Grotthus S, Vogt J, et al. Excitability regulation in the dorsomedial prefrontal cortex during sustained instructed fear responses: a TMS-EEG study. *Sci Rep*. 2018;8(1):1–12.
34. Chirumamilla VC, Gonzalez-Escamilla G, Koirala N, Bonertz T, von Grotthus S, Muthuraman M, et al. Cortical excitability dynamics during fear processing. *Front Neurosci*. 2019;13:568.
35. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology*. 1983;33(11):1444–52.
36. Goretti B, Portaccio E, Zipoli V, Hakiki B, Siracusa G, Sorbi S, et al. Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. *Neurol Sci*. 2009;30(1):15–20.
37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67(6):361–70.
38. Holmes AJ, Hollinshead MO, O'Keefe TM, Petrov VI, Fariello GR, Wald LL, et al. Brain genomics superstruct project initial data release with structural, functional, and behavioral measures. *Sci Data*. 2015;2: 150031.
39. Fischl B. FreeSurfer. *Neuroimage*. 2012;62(2):774–81.
40. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. *Neuroimage*. 2012;61(4):1402–18.
41. Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*. 2006;31(3):968–80.
42. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron*. 2002;33(3):341–55.
43. Esteban O, Markiewicz CJ, Blair RW, Moodie CA, Isik AI, Erramuzpe A, et al. fMRIPrep: a robust preprocessing pipeline for functional MRI. *Nat Methods*. 2019;16(1):111–6.
44. Corp DT, Joutsa J, Darby RR, Delnooz CCS, van de Warrenburg BPC, Cooke D, et al. Network localization of cervical dystonia based on causal brain lesions. *Brain J Neurol*. 2019;142(6):1660–74.
45. Boes AD, Prasad S, Liu H, Liu Q, Pascual-Leone A, Caviness VS Jr, et al. Network localization of neurological symptoms from focal brain lesions. *Brain J Neurol*. 2015;138(Pt 10):3061–75.
46. Darby RR, Joutsa J, Burke MJ, Fox MD. Lesion network localization of free will. *Proc Natl Acad Sci USA*. 2018;115(42):10792–7.
47. Meyer B, Yuen KS, Ertl M, Polomac N, Mulert C, Buchel C, et al. Neural mechanisms of placebo anxiolysis. *J Neurosci*. 2015;35(19):7365–73.
48. Ferree TC, Luu P, Russell GS, Tucker DM. Scalp electrode impedance, infection risk, and EEG data quality. *Clin Neurophysiol*. 2001;112(3):536–44.
49. Oostenveld R, Fries P, Maris E, Schoffelen JM. FieldTrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data. *Comput Intell Neurosci*. 2011;2011: 156869.

50. Hyvarinen A. Fast and robust fixed-point algorithms for independent component analysis. *IEEE Trans Neural Netw.* 1999;10(3):626–34.
51. Michels L, Muthuraman M, Anwar AR, Kollias S, Leh SE, Riese F, et al. Changes of functional and directed resting-state connectivity are associated with neuronal oscillations, ApoE genotype and amyloid deposition in mild cognitive impairment. *Front Aging Neurosci.* 2017;9:304.
52. Chien JH, Colloca L, Korzeniewska A, Cheng JJ, Campbell CM, Hillis AE, et al. Oscillatory EEG activity induced by conditioning stimuli during fear conditioning reflects salience and valence of these stimuli more than expectancy. *Neuroscience.* 2017;346:81–93.
53. Chiosa V, Groppa SA, Ciolac D, Koirala N, Misina L, Winter Y, et al. Break-down of thalamo-cortical connectivity precedes spike generation in focal epilepsies. *Brain Connect.* 2017;7(5):309–20.
54. Muthuraman M, Raethjen J, Koirala N, Anwar AR, Mideksa KG, Elble R, et al. Cerebello-cortical network fingerprints differ between essential, Parkinson's and mimicked tremors. *Brain J Neurol.* 2018;141(6):1770–81.
55. Kaminski M, Ding M, Truccolo WA, Bressler SL. Evaluating causal relations in neural systems: granger causality, directed transfer function and statistical assessment of significance. *Biol Cybern.* 2001;85(2):145–57.
56. Arnold N, Tapio S. Estimation of parameters and eigenmodes of multivariate autoregressive models. *ACM Trans Math Softw.* 2001;27(1):21–57.
57. Tapio S, Arnold N. Algorithm 808: ARfit: a matlab package for the estimation of parameters and eigenmodes of multivariate autoregressive models. *ACM Trans Math Softw.* 2001;27(1):58–65.
58. Haufe S, Nikulin VV, Muller KR, Nolte G. A critical assessment of connectivity measures for EEG data: a simulation study. *Neuroimage.* 2013;64:120–33.
59. McDonald RP, Ho MH. Principles and practice in reporting structural equation analyses. *Psychol Methods.* 2002;7(1):64–82.
60. Kelley K, Lai K. Accuracy in parameter estimation for the root mean square error of approximation: sample size planning for narrow confidence intervals. *Multivar Behav Res.* 2011;46(1):1–32.
61. Maris E, Oostenveld R. Nonparametric statistical testing of EEG- and MEG-data. *J Neurosci Methods.* 2007;164(1):177–90.
62. Takagi Y, Sakai Y, Abe Y, Nishida S, Harrison BJ, Martinez-Zalacain I, et al. A common brain network among state, trait, and pathological anxiety from whole-brain functional connectivity. *Neuroimage.* 2018;172:506–16.
63. Kim MJ, Whalen PJ. The structural integrity of an amygdala-prefrontal pathway predicts trait anxiety. *J Neurosci.* 2009;29(37):11614–8.
64. Jalbrzikowski M, Larsen B, Hallquist MN, Foran W, Calabro F, Luna B. Development of white matter microstructure and intrinsic functional connectivity between the amygdala and ventromedial prefrontal cortex: associations with anxiety and depression. *Biol Psychiatry.* 2017;82(7):511–21.
65. Wager TD, Davidson ML, Hughes BL, Lindquist MA, Ochsner KN. Prefrontal-subcortical pathways mediating successful emotion regulation. *Neuron.* 2008;59(6):1037–50.
66. Liu WZ, Zhang WH, Zheng ZH, Zou JX, Liu XX, Huang SH, et al. Identification of a prefrontal cortex-to-amygdala pathway for chronic stress-induced anxiety. *Nat Commun.* 2020;11(1):2221.
67. Kolesar TA, Bilevicius E, Wilson AD, Kornelsen J. Systematic review and meta-analyses of neural structural and functional differences in generalized anxiety disorder and healthy controls using magnetic resonance imaging. *NeuroImage Clin.* 2019;24: 102016.
68. Mochcovitch MD, da Rocha Freire RC, Garcia RF, Nardi AE. A systematic review of fMRI studies in generalized anxiety disorder: evaluating its neural and cognitive basis. *J Affect Disord.* 2014;167:336–42.
69. Shang J, Fu Y, Ren Z, Zhang T, Du M, Gong Q, et al. The common traits of the ACC and PFC in anxiety disorders in the DSM-5: meta-analysis of voxel-based morphometry studies. *PLoS ONE.* 2014;9(3): e93432.
70. Gold AL, Steuber ER, White LK, Pacheco J, Sachs JF, Pagliaccio D, et al. Cortical thickness and subcortical gray matter volume in pediatric anxiety disorders. *Neuropsychopharmacology.* 2017;42(12):2423–33.
71. Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. *Nat Rev Neurol.* 2014;10(9):507–17.
72. de Jong BA, Uitdehaag BM. Anxiety is more important than depression in MS—commentary. *Mult Scler.* 2018;24(4):444–5.
73. Rossi S, Studer V, Motta C, Polidoro S, Perugini J, Macchiarelo G, et al. Neuroinflammation drives anxiety and depression in relapsing–remitting multiple sclerosis. *Neurology.* 2017;89(13):1338–47.
74. Marrie RA, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, et al. The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. *Mult Scler Relat Disord.* 2018;20:9–15.
75. Andreescu C, Tudorascu D, Sheu LK, Rangarajan A, Butters MA, Walker S, et al. Brain structural changes in late-life generalized anxiety disorder. *Psychiatry Res Neuroimaging.* 2017;268:15–21.
76. Wager T. The roles of medial prefrontal cortex in emotion: neuroimaging evidence for functional subdivisions and cortical-subcortical pathways. *Biol Psychiatry.* 2008;63(7):151s.
77. Veldsman M. Atrophy network mapping of transdiagnostic cognitive and neuropsychiatric symptoms. *Brain J Neurol.* 2020;143(4):1053–6.
78. Morgane PJ, Galler JR, Mokler DJ. A review of systems and networks of the limbic forebrain/limbic midbrain. *Prog Neurobiol.* 2005;75(2):143–60.
79. Monk CS, Telzer EH, Mogg K, Bradley BP, Mai X, Louro HM, et al. Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder. *Arch Gen Psychiatry.* 2008;65(5):568–76.
80. Carrera E, Tononi G. Diaschisis: past, present, future. *Brain J Neurol.* 2014;137(Pt 9):2408–22.
81. Ferreri F, Vecchio F, Vollero L, Guerra A, Petrichella S, Ponzio D, et al. Sensorimotor cortex excitability and connectivity in Alzheimer's disease: a TMS-EEG co-registration study. *Hum Brain Mapp.* 2016;37(6):2083–96.
82. Ironside M, Browning M, Ansari TL, Harvey CJ, Sekyi-Djan MN, Bishop SJ, et al. Effect of prefrontal cortex stimulation on regulation of amygdala response to threat in individuals with trait anxiety: a randomized clinical trial. *JAMA Psychiat.* 2019;76(1):71–8.
83. Fiene M, Rufener KS, Kuehne M, Matzke M, Heinze HJ, Zaehle T. Electrophysiological and behavioral effects of frontal transcranial direct current stimulation on cognitive fatigue in multiple sclerosis. *J Neurol.* 2018;265(3):607–17.
84. Charvet LE, Dobbs B, Shaw MT, Bikson M, Datta A, Krupp LB. Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: results from a randomized, sham-controlled trial. *Mult Scler.* 2018;24(13):1760–9.
85. Hanken K, Bosse M, Mohrke K, Eling P, Kastrup A, Antal A, et al. Counteracting fatigue in multiple sclerosis with right parietal anodal transcranial direct current stimulation. *Front Neurol.* 2016;7:154.
86. Mattioli F, Bellomi F, Stampatori C, Capra R, Miniussi C. Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis. *Mult Scler.* 2016;22(2):222–30.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

